Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08642534 in Adults With Obesity
NCT07731139Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing PF-08642534 with Placebo (2 arms). Primary endpoint: Incidence of treatment emergent adverse events at 8 weeks. Started Jul 2026; status: recruiting.
02
Drugs
PF-08642534
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07731139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07731139.